Regulated Information - Denominator
Original post:
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
Accomplished executive with over two decades of senior biotechnology expertise joins Kane’s Board of Directors Accomplished executive with over two decades of senior biotechnology expertise joins Kane’s Board of Directors
See more here:
Kane Biotech Strengthens Board with Biotech Executive
TAMPA, Fla., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, today announced its research partner, Aimia Pet HealthCo. Inc. (APH), has signed a memorandum of understanding (MOU) with KGK Science Inc. (KGK) for the development of a GLP1 supplement for pets.
Read the original post:
Better Choice Research Partner, Aimia Pet HealthCo Inc., Signs Second R&D Partnership Agreement with KGK Science for Development of GLP1 Supplement...
Myriad expands pharma service offering by introducing Personalis’ ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx cancer tests Myriad expands pharma service offering by introducing Personalis’ ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx cancer tests
See the original post here:
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
DALLAS, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc., a leader in the development of personalized anti-cancer cellular therapies for patients with solid tumors, announced today that it has been awarded a $9.9 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The funds will be used to support the company's Phase 2 clinical study of Vigil® in platinum-sensitive patients who have recurrent ovarian cancer with a homologous recombination proficient (HRP) molecular profile. These patients face an acutely high unmet medical need due to the removal of PARP inhibitor therapies in 2022. The study is designed as a pivotal trial to confirm the positive survival results seen in ovarian cancer patients with the HRP profile tumors in Gradalis’ earlier VITAL study in frontline maintenance therapy. The company intends to pursue accelerated approval based on positive results.
Originally posted here:
Gradalis Awarded $9.9 Million Grant From the Cancer Prevention and Research Institute of Texas
TAIPEI, Taiwan and SAN DIGEO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550), today announced that the Company has initiated the rolling submission of its Biologic License Application (BLA) for ADI-PEG 20 to the U.S. Food and Drug Administration (FDA) for the systemic treatment of patients with malignant pleural mesothelioma with non-epithelioid histology, in combination with a platinum agent and pemetrexed. This submission is based on the results of the successful phase 3 trial of ADI-PEG 20 in combination with a platinum agent and pemetrexed which met both its primary and secondary objectives for progression free survival and overall survival. The rolling submission process allows for the submission of individual modules of the BLA as they are completed, which can streamline the regulatory review process and may expedite the potential approval timeline.
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 16, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the highlights from its “ACLF Day” held on November 11, 2023 during AASLD The Liver Meeting ® in Boston, MA (USA).
Read the rest here:
GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023
Arecor Therapeutics plc(“Arecor” or the “Group”)
See more here:
First Product Incorporating Arecor’s Arestat Technology, At220, Launched in Europe
LONDON and RALEIGH, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces its President and CEO, David Zaccardelli, has won ‘Executive of the Year 2023’ at the SCRIP Awards in recognition of his exemplary leadership.
Follow this link:
Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award